View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 19, 2021updated 11 Jul 2022 9:50am

NRx Pharmaceuticals reports positive data from Covid-19 trial of Zyesami

The DSMB found no new safety concerns linked to the experimental therapy in hospitalised Covid-19 patients.

NRx Pharmaceuticals has reported positive safety data from the National Institutes of Health (NIH)-sponsored Phase III ACTIV-3 Critical Care clinical trial of Zyesami (aviptadil) in Covid-19 patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An experimental drug, Zyesami is a synthetic form of a vasoactive intestinal polypeptide (VIP), which selectively attaches to the alveolar type II cell (ATII) in the lung’s air sac (alveolus).

VIP is created naturally in the body and can potentially offer lung-protective, anti-viral and anti-inflammatory effects.

The randomised, blinded, placebo-controlled trial is analysing Zyesami as monotherapy or along with antiviral drug, remdesivir, in hospitalised Covid-19 patients with acute respiratory failure.

These subjects needed high-flow supplemental oxygen delivered by nasal cannula, mechanical ventilation, or extracorporeal membrane oxygenation.

Study investigators categorised the trial subjects to receive one of the four therapy regimens of both Zyesami and remdesivir or Zyesami and placebo or remdesivir and placebo or just placebo, apart from the standard of care.

Zyesami is given as a daily 12-hour intravenous dose for three days.

The Data Safety Monitoring Board (DSMB) reported no new safety concerns in ACTIV-3 reviewed data from nearly 140 subjects and advised continuing the subject enrolment.

ACTIV-3 is one among the three trials of Zyesami progressing in severe or critical Covid-19 patients.

Zyesami received fast track designation from the US Food and Drug Administration (FDA) for use in Covid-19 patients.

Earlier this month, NRx Pharmaceuticals entered an agreement with MannKind to create a dry powder formulation of Zyesami for the treatment of various respiratory ailments.

The company reported in July that Zyesami statistically significantly prevented a steep surge in cytokines or cytokine storm in Covid-19 patients in a Phase IIb/III trial.

The trial’s prespecified goal was to analyse the change in cytokine level, as cytokines are linked to mortality in Covid-19 patients.

Apart from Zyesami, NRx Pharmaceuticals is developing an experimental drug, NRX-101, for the treatment of suicidal bipolar depression.

NRX-101 is presently being analysed in Phase III trials with data readouts anticipated next year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology